Patents Assigned to Curara AB
  • Citrullinated peptides that bind to types of MHC class II and their use on diagnosis and treatment
    Patent number: 12180265
    Abstract: A pharmaceutical composition comprises (a) a peptide of 8 to 20 amino acids comprising at least one citrulline residue and 13, 14 or 15 consecutive amino acids residues with a sequence present in SEQ ID NO 22 or a complex of said peptide and a human recombinant MHC class II protein, and (b) an immunologic adjuvant.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: December 31, 2024
    Assignee: Curara AB
    Inventors: Lars Klareskog, Vivianne Malmstström
  • SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
    Publication number: 20240010703
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Application
    Filed: August 22, 2023
    Publication date: January 11, 2024
    Applicants: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James MATTHAEI, Anne-Renee VAN DER VUURST DE VRIES, Joshua BEILKE, Vivianne MALMSTRÖM, Kathryn HOOPER, Rebecca JOHNSON, Lars KLARESKOG
  • Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory T cells to treat autoimmune diseases
    Patent number: 11753457
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: September 12, 2023
    Assignees: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James Matthaei, Anne-Renee van der Vuurst de Vries, Joshua Beilke, Vivianne Malmström, Kathryn Hooper, Rebecca Johnson, Lars Klareskog
  • SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
    Publication number: 20230080155
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 16, 2023
    Applicants: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James MATTHAEI, Anne-Renee Van Der Vuurst De Vries, Joshua Beilke, Vivianne Malmstrom, Kathryn Hooper, Rebecca Johnson, Lars Klareskog